Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors

Pfizer, UPS, and Kraft are all high-yielding stocks that come with varying levels of risk. They're all generating positive free cash flow, but their payout ratios don't look good.

Pfizer is upgraded to buy, supported by a low valuation, strong free cash flow, and a high 6.2% dividend yield. PFE delivered a Q2 double beat, raised full-year revenue guidance, and benefits from pipeline progress, though COVID-19 product sales guidance was trimmed. Technical momentum is building, with a golden cross and bullish rounded bottom pattern, but resistance remains near $30.

Pfizer Inc. (PFE) Presents at U.S. All Stars Conference Transcript